-
Je něco špatně v tomto záznamu ?
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin
P. Gontero, R. Sylvester, F. Pisano, S. Joniau, M. Oderda, V. Serretta, S. Larré, S. Di Stasi, B. Van Rhijn, AJ. Witjes, AJ. Grotenhuis, R. Colombo, A. Briganti, M. Babjuk, V. Soukup, PU. Malmström, J. Irani, N. Malats, J. Baniel, R. Mano, T....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
NLK
Free Medical Journals
od 1999
Medline Complete (EBSCOhost)
od 1999-01-01 do Před 1 rokem
PubMed
26469362
DOI
10.1111/bju.13354
Knihovny.cz E-zdroje
- MeSH
- adjuvancia imunologická terapeutické užití MeSH
- BCG vakcína terapeutické užití MeSH
- cystektomie metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory močového měchýře farmakoterapie patologie chirurgie MeSH
- reoperace MeSH
- retrospektivní studie MeSH
- senioři MeSH
- staging nádorů MeSH
- stupeň nádoru MeSH
- uretra MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
OBJECTIVES: To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). PATIENTS AND METHODS: In a large retrospective multicentre cohort of 2451 patients with T1-HG/G3 initially treated with bacille Calmette-Guérin, 935 (38%) had a re-TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re-TUR), group 2 (no muscle, re-TUR), group 3 (muscle, no re-TUR) and group 4 (muscle, re-TUR). Clinical outcomes were compared across the four groups. RESULTS: Re-TUR had a positive impact on recurrence, progression, CSS and OS only if muscle was not present in the primary TUR specimen. Adjusting for the most important prognostic factors, re-TUR in the absence of muscle had a borderline significant effect on time to recurrence [hazard ratio (HR) 0.67, P = 0.08], progression (HR 0.46, P = 0.06), CSS (HR 0.31, P = 0.07) and OS (HR 0.48, P = 0.05). Re-TUR in the presence of muscle in the primary TUR specimen did not improve the outcome for any of the endpoints. CONCLUSIONS: Our retrospective analysis suggests that re-TUR may not be necessary in patients with T1-HG/G3, if muscle is present in the specimen of the primary TUR.
Department of Experimental and Clinical Medicine University of Florence Florence Italy
Department of Surgical Oncological and Stomatological Sciences University of Palermo Palermo Italy
Department of Surgical Science John Radcliffe Hospital University of Oxford Oxford UK
Department of Urology Academic Hospital Uppsala University Uppsala Sweden
Department of Urology Fundacio Puigvert University of Barcelona Barcelona Spain
Department of Urology Mayo Clinic Rochester MN USA
Department of Urology Memorial Sloan Kettering Cancer Center New York NY USA
Department of Urology Motol Hospital University of Praha Praha Czech Republic
Department of Urology Rabin Medical Centre Tel Aviv Israel
Department of Urology Radboud University Nijmegen Medical Centre Nijmegen The Netherlands
Department of Urology Santa Chiara Hospital Trento Italy
Department of Urology Sismanoglio Hospital University of Athens Athens Greece
Department of Urology Weill Medical College of Cornell University in New York City New York NY USA
Dipartimento di Urologia Università Vita Salute Ospedale S Raffaele Milan Italy
Facharzt fur Urologie Abteilung fur Urologie Chirurgische Universitats klinik Freiburg Germany
Formerly Department of Biostatistics EORTC Headquarters Brussels Belgium
Genetic and Molecular Epidemiology Group Spanish National Cancer Research Centre Madrid Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17024221
- 003
- CZ-PrNML
- 005
- 20170829113353.0
- 007
- ta
- 008
- 170720s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bju.13354 $2 doi
- 035 __
- $a (PubMed)26469362
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Gontero, Paolo $u Urology Clinic, Città della Salute e della Scienza di Torino, University of Studies of Turin, Turin, Italy.
- 245 14
- $a The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin / $c P. Gontero, R. Sylvester, F. Pisano, S. Joniau, M. Oderda, V. Serretta, S. Larré, S. Di Stasi, B. Van Rhijn, AJ. Witjes, AJ. Grotenhuis, R. Colombo, A. Briganti, M. Babjuk, V. Soukup, PU. Malmström, J. Irani, N. Malats, J. Baniel, R. Mano, T. Cai, EK. Cha, P. Ardelt, J. Vakarakis, R. Bartoletti, G. Dalbagni, SF. Shariat, E. Xylinas, RJ. Karnes, J. Palou,
- 520 9_
- $a OBJECTIVES: To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). PATIENTS AND METHODS: In a large retrospective multicentre cohort of 2451 patients with T1-HG/G3 initially treated with bacille Calmette-Guérin, 935 (38%) had a re-TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re-TUR), group 2 (no muscle, re-TUR), group 3 (muscle, no re-TUR) and group 4 (muscle, re-TUR). Clinical outcomes were compared across the four groups. RESULTS: Re-TUR had a positive impact on recurrence, progression, CSS and OS only if muscle was not present in the primary TUR specimen. Adjusting for the most important prognostic factors, re-TUR in the absence of muscle had a borderline significant effect on time to recurrence [hazard ratio (HR) 0.67, P = 0.08], progression (HR 0.46, P = 0.06), CSS (HR 0.31, P = 0.07) and OS (HR 0.48, P = 0.05). Re-TUR in the presence of muscle in the primary TUR specimen did not improve the outcome for any of the endpoints. CONCLUSIONS: Our retrospective analysis suggests that re-TUR may not be necessary in patients with T1-HG/G3, if muscle is present in the specimen of the primary TUR.
- 650 _2
- $a adjuvancia imunologická $x terapeutické užití $7 D000276
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a BCG vakcína $x terapeutické užití $7 D001500
- 650 _2
- $a cystektomie $x metody $7 D015653
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a reoperace $7 D012086
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a uretra $7 D014521
- 650 _2
- $a nádory močového měchýře $x farmakoterapie $x patologie $x chirurgie $7 D001749
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Sylvester, Richard $u Formerly Department of Biostatistics, EORTC Headquarters, Brussels, Belgium.
- 700 1_
- $a Pisano, Francesca $u Urology Clinic, Città della Salute e della Scienza di Torino, University of Studies of Turin, Turin, Italy.
- 700 1_
- $a Joniau, Steven $u Oncologic and Reconstructive Urology, Department of Urology, University Hospitals Leuven, Leuven, Belgium.
- 700 1_
- $a Oderda, Marco $u Urology Clinic, Città della Salute e della Scienza di Torino, University of Studies of Turin, Turin, Italy.
- 700 1_
- $a Serretta, Vincenzo $u Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy.
- 700 1_
- $a Larré, Stéphane $u Department of Surgical Science, John Radcliffe Hospital, University of Oxford, Oxford, UK.
- 700 1_
- $a Di Stasi, Savino $u Policlinico Tor Vergata-University of Rome, Rome, Italy.
- 700 1_
- $a Van Rhijn, Bas $u Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- 700 1_
- $a Witjes, Alfred J $u Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
- 700 1_
- $a Grotenhuis, Anne J $u Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
- 700 1_
- $a Colombo, Renzo $u Dipartimento di Urologia, Università Vita-Salute. Ospedale S. Raffaele, Milan, Italy.
- 700 1_
- $a Briganti, Alberto $u Dipartimento di Urologia, Università Vita-Salute. Ospedale S. Raffaele, Milan, Italy.
- 700 1_
- $a Babjuk, Marek $u Department of Urology, Motol Hospital, University of Praha, Praha, Czech Republic.
- 700 1_
- $a Soukup, Viktor $u Department of Urology, Motol Hospital, University of Praha, Praha, Czech Republic.
- 700 1_
- $a Malmström, Per-Uno $u Department of Urology, Academic Hospital, Uppsala University, Uppsala, Sweden.
- 700 1_
- $a Irani, Jacques $u Department of Urology, Centre Hospitalier Universitaire La Milétrie, University of Poitiers, Poitiers, France.
- 700 1_
- $a Malats, Nuria $u Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
- 700 1_
- $a Baniel, Jack $u Department of Urology, Rabin Medical Centre, Tel Aviv, Israel.
- 700 1_
- $a Mano, Roy $u Department of Urology, Rabin Medical Centre, Tel Aviv, Israel.
- 700 1_
- $a Cai, Tommaso $u Department of Urology, Santa Chiara Hospital, Trento, Italy.
- 700 1_
- $a Cha, Eugene K $u Department of Urology, Weill Medical College of Cornell University in New York City, New York, NY, USA.
- 700 1_
- $a Ardelt, Peter $u Facharzt fur Urologie, Abteilung fur Urologie. Chirurgische Universitats klinik, Freiburg, Germany. $7 gn_A_00008168
- 700 1_
- $a Vakarakis, John $u Department of Urology, Sismanoglio Hospital, University of Athens, Athens, Greece.
- 700 1_
- $a Bartoletti, Riccardo $u Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
- 700 1_
- $a Dalbagni, Guido $u Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Weill Medical College of Cornell University in New York City, New York, NY, USA.
- 700 1_
- $a Xylinas, Evanguelos $u Department of Urology, Weill Medical College of Cornell University in New York City, New York, NY, USA.
- 700 1_
- $a Karnes, Robert J $u Department of Urology, Mayo Clinic, Rochester, MN, USA.
- 700 1_
- $a Palou, Joan $u Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain.
- 773 0_
- $w MED00011371 $t BJU international $x 1464-410X $g Roč. 118, č. 1 (2016), s. 44-52
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26469362 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170829113940 $b ABA008
- 999 __
- $a ok $b bmc $g 1239902 $s 985134
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 118 $c 1 $d 44-52 $e 20151106 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
- LZP __
- $a Pubmed-20170720
